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Introduction: There is growing knowledge of the wide ranging effects of histamine
throughout the body therefore it is important to better understand the effects of this
amine in patients with asthma. We aimed to explore the association between histamine
pharmacodynamic (PD) response and genetic variation in the histamine pathway in
children with asthma.
Methods: Histamine Iontophoresis with Laser Doppler Monitoring (HILD) was performed
in children with asthma and estimates for area under the effect curve (AUEC), maximal
response over baseline (Emax), and time of Emax (Tmax) were calculated using
non-compartmental analysis and non-linear mixed-effects model with a linked effect
PK/PD model. DNA isolation and genotyping were performed among participants to
detect known single nucleotide polymorphisms (SNPs) (n = 10) among genes (HDC,
HNMT, ABP1, HRH1, HRH4) within the histamine pathway. General linear model was
used to identify associations between histamine related genetic variants and measured
histamine PD response parameters.
Results: Genotyping and HILD response profiles were completed for 163 children.
ABP1 47 C/T, ABP1 4107, and HNMT-1639 C/Twere associated with Emax (ABP1
47 CC genotype mean Emax 167.21 vs. CT/TT genotype mean Emax 139.20,
p = 0.04; ABP1 4107 CC genotype mean Emax 141.72 vs. CG/GG genotype
mean Emax 156.09, p = 0.005; HNMT-1639 CC genotype mean Emax 132.62
vs. CT/TT genotype mean Emax 155.3, p = 0.02). In a stratified analysis among
African American children only, ABP1 and HNMT SNPs were also associated with
PD response; HRH4 413 CC genotype was associated with lower Emax, p = 0.009.
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Conclusions: We show for the first time that histamine pathway genetic variation is
associated with measureable changes in histamine response in children with asthma. The
variability in histamine response and impact of histamine pathway genotype is important
to further explore in patients with asthma so as to improve disease phenotyping leading
to more personalized treatments.
Keywords: histamine, pharmacodynamics, pharmacogenetics, asthma, biomarker
INTRODUCTION
Asthma is among the most common chronic diseases in children
and adults. Despite considerable advances in the treatment of
the disease, many patients continue to experience persistent
symptoms. It is reported that up to 50% of children do
not achieve adequate asthma control on top line therapies
such as inhaled steroids (Szefler et al., 2002). It is important
to better understand the inflammatory mediators involved in
asthma pathogenesis so as to improve disease phenotyping
and therapeutic outcomes. Histamine is an important mediator
in the pathophysiology of asthma in children and adults.
In addition to mediating symptoms of the allergic response
(e.g., itching, sneezing, rhinitis), the amine exerts effects
in the lung. Inhalation of histamine in the lung causes
direct bronchoconstriction. Furthermore, activation of histamine
receptors (H1, H2, H3, H4) throughout the body results in
cytokine production, is involved in dendritic cell regulation, and
modifies the Th1 and Th2 responses (Jones and Kearns, 2011).
Antihistamines have been shown to be beneficial in reducing
asthma exacerbations and even decreasing risk of asthma
among those with specific asthma phenotypes (e.g., allergic
asthma) (Grant et al., 1995; Warner, 2001). Understanding
histamine pharmacodynamic (PD) response profiles in patients
with asthma may provide an important surrogate endpoint
for improving phenotyping asthma and for the evaluation of
the effects of histamine in disease pathogenesis and treatment
response.
Epicutaneous histamine testing (e.g., skin prick test) is the
gold standard method for the evaluation of allergic disease in
adults and children. The method is also used as a PD marker
in the evaluation of antihistamine efficacy and duration of effect.
PD histamine response may also be important in discriminating
asthma phenotypes which may most significantly benefit from
therapeutic agents that affect the allergic response pathway via
interruption of the histamine response (e.g., antihistamines). We
have previously reviewed the benefits of Histamine Iontophoresis
with Laser Doppler monitoring (HILD) vs. the standard
the epicutaneous skin prick test in discerning differences in
histamine response between individuals. We observed that HILD
provides a dynamic and robust characterization of histamine
response (Jones et al., 2009). Additionally, among children with
allergic rhinitis we observed that pharmacodynamic response
to histamine varies among children and adults with allergic
disease whereby children were able to be classified into distinct
groups based on the magnitude of response profiles (Jones
et al., 2013). Differences in the biological response to histamine
may be relevant to disease pathogenesis and to therapeutic
response to treatments that attenuate histamine action (e.g.,
antihistamines).
The histamine production, response, and degradation
pathway includes: Histadine decarboxylase (HDC), responsible
for production of histamine from histidine; H1-receptor (H1R),
H2-receptor(H2R), H3-receptor (H3R), H4-receptor (H4R),
receptors responsible for exerting histamine effects in the
body; Histamine-N-methlytransferase (HNMT), responsible for
degradation of ∼80% of histamine in the body for elimination;
and Diamine Oxidase (DAO), responsible for degradation
of ∼20% of histamine in the body for elimination(Jones and
Kearns, 2011). Genetic variation within genes responsible for
histamine production (HDC), response (HRH1, HRH4), and
degradation (HNMT, ABP1) have been previously described
(García-Martín et al., 2009). Single nucleotide polymorphisms
(SNP) in these genes have been associated with asthma and
allergic disease in children and adults of different racial and
ethnic populations. We have previously observed that variants
in HRH1 and HNMT were associated with allergic asthma
in children and specifically among African American children
(Anvari et al., 2015). Although, several SNPs have been associated
with allergic disease and asthma, the functional relevance of
the majority of variants is unknown. The most thoroughly
investigated SNP within the histamine pathway is HNMT
314 C/T. This SNP has been shown to result in alterations in
protein folding of the enzyme and decreased enzymatic activity
and has been associated with asthma and atopic dermatitis
(Kennedy et al., 2008; Szczepankiewicz et al., 2010). Defects in
histamine degradation may lead to accumulation of the amine
and exaggerated and/or prolonged response to histamine at the
receptor. Defects in histamine handling and/or alterations at
the receptor may alter disease pathogenesis and antihistamine
efficacy. Therefore, the aim of our study reported here was to
explore genetic variation within the histamine pathway genes
in relation to histamine pharmacodynamic response in children
with asthma.
MATERIALS AND METHODS
Study Population
All study participants were enrolled via convenience sampling
in this cross-sectional study after obtaining parental
permission and, when appropriate (i.e., age ≥ 7), child
assent. This study was approved by the Children’s Mercy
Institutional Review Board (IRB# 10-10-192). Children
with asthma were enrolled from Allergy, Asthma, and
Immunology outpatient clinics at Children’s Mercy in
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Kansas City, MO. Asthma was defined by ≥12% post-
bronchodilator reversibility in forced expiratory volume
in 1 s (FEV1) or by an Allergy/Asthma specialist diagnosis
based on clinical symptoms in children unable to perform
spirometry. All participants discontinued antihistamines
(H1 receptor and H2 receptor inverse agonists) at least 10
days prior to the study and could not have used tricyclic
antidepressants or systemic steroids 30 days prior to study
participation.
HILD
HILD was performed on the anterior surface of the forearm
as previously described (Jones et al., 2009). A solid-state,
single-frequency laser probe was inserted into the center of
an iontophoresis chamber attached to a laser Doppler blood
flow monitor (DRT4, Moor Instruments Ltd, Wilmington,
Delaware) on the volar surface of the forearm. A second
laser Doppler control probe was placed at a distance of at
least 1 cm from the iontophoresis site as per previously
described methods. Then, 200µL of histamine dihydrochloride
solution (1%) (Sigma Chemical Ltd, Dorset, UK), dissolved
in a 2% methylcellulose gel (Sigma Chemical Co, St Louis,
Missouri) was placed in the reservoir of the iontophoresis
chamber. A platinum electrode in the iontophoresis chamber
was connected to the positive terminal of a constant current
source. For iontophoresis, constant anodal current (50µA)
was applied for 10 s. Values for small vessel blood flow at
each of the probe sites were simultaneously calculated by
software package provided by the manufacturer (Version2,
Moor Instruments Ltd, Devon, UK) and given in perfusion
units (flux). Baseline small vessel blood flow was assessed
for 2 min before histamine iontophoresis. After histamine
iontophoresis, blood flow was continuously assessed until blood
flow measurements returned to baseline or for a total period up
to 2 h.
Data collected from HILD monitoring was re-sampled
using an averaging algorithm. The raw individual data (up
to 3600 data points per subject) was first evenly divided
into 200 segments with each containing approximately 18
observations. Within each segment, every data point was
examined for potential outliers based on interquartile range
rule. An averaged signal was calculated by taking the mean
of signals within each segment. The corresponding time was
assigned by taking the median time point within the segment.
With this approach, each individual data set was reduced to
200 observations. A final screening was conducted manually to
select 10–15 data points per subject to further reduce the size,
while maintaining a realistic representation of the histamine
response over time curve. The re-sampled data sets were then
pooled together and subjected to pharmacometric modeling.
NONMEM v7.3 (ICON Dev. Soln., Ellicott City, MD) was used
to build the population PK/PD model. A population PK/PD
linked effect model was developed to describe the histamine
response over time monitored by HILD. Secondary modeling
analysis provided parameter estimates for area under the effect
curve (AUEC), and relative maximal response over baseline
(Emax) and time of maximal response (Tmax) (Liu et al.,
2016).
DNA Extraction and Genotyping
Five milliliter of blood was collected into a glass tube containing
ACD or calcium EDTA anticoagulant, mixed by repeated
inversion and either stored for up to 7 days at 4◦C or immediately
frozen at −80◦C. Genomic DNA was extracted from blood
using the Illustra Blood Genomic Prep Mini Spin Kit (GE
Healthcare, Piscataway, NJ). Genotyping assays were performed
on genomic DNA (12–16 ng) using commercially available
TaqMan assays to detect the following SNPs of interest: rs1049793
(ABP1 47 C/T), rs10156191 (ABP1 4107 C/G), rs1049742 (ABP1
995 C/T), rs17740607 (HDC 92 C/T), rs901865 (HRH1-17
C/T), rs11665084 (HRH4 413 C/T), rs6430764 (HNMT-1639
C/T), rs2071048 (HNMT 464 C/T), rs1050900 (HNMT 3′UTR
A/T), and rs11558538 (HNMT 314 C/T) (Applied Biosystems,
Foster City, CA) and KAPA Probe Fast qPCR master mix
(Kapa Biosystems, Boston, MA) according to manufacturer’s
recommendations. SNPs were chosen based on their potential
functional significance and previously investigated variants (see
Supplementary Table 1), as well as those with an expected minor
allele frequency (MAF) ≥2% within our expected participant
population (Preuss et al., 1998; Sasaki et al., 2000; Hon et al.,
2006; García-Martín et al., 2009). All samples were performed in
duplicates to rule out random error.
Statistical Analysis
Concordance with Hardy-Weinberg equilibrium was confirmed
for each SNP using available online software (Rodriguez,
2008). General linear model was used to compare genotype to
pharmacodynamic parameters Emax, Tmax, and AUEC. Data
were corrected for race and asthma type (allergic vs. non-
allergic). Allergic categorization was defined by at least one
positive skin prick test to a panel of common aeroallergens. In
the dominant analysis, three genotypes were reclassified as wild
type vs. non-wild type. In the stratified analysis, subjects were
divided by race and analyzed within Caucasians and African
Americans separately. Statistical significance was claimed with
p-value < 0.05. Statistical analyses were performed using SAS 9.4
(Cary, NC).
RESULTS
N = 163 children were included in the final analysis of the study.
Patient demographics are presented in Table 1.
Emax and Tmax values were associated with genotype for
ABP1 and HNMT after correcting for race and asthma type.
Genotype analysis revealed differences in Emax for ABP1 4107
C/G SNP (CC 141.72; CG 161.4; GG 142.06, p = 0.007). We
also found an association between genotype and Tmax for
HNMT 3′UTR A/T (AA 18.87, AT 18.48, TT 40.46, p = 0.001)
(Supplementary Table 2).
Dominant genotype analysis revealed an association of Emax
with ABP1 47 C/T, ABP1 4107 C/G, and HNMT-1639 C/T
SNPs (ABP1 47 C/T, CC 167.21 vs. CT/TT 139.20, p = 0.04;
ABP1 4107 C/G, CC 141.72 vs. CG/GG 156.09, p = 0.005;
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HNMT-1639 C/T, CC 132.62 vs. CT/TT 155.3, p = 0.02)
(Figure 1).
We did not observe an association between other
investigated SNPs and pharmacodynamic response for
(Supplementary Table 2).
We conducted further analysis of the relationship between
genotype and pharmacodynamic response among stratified
racial groups as asthma phenotype and/or pathophysiology
may differ according to race. In a dominant genotype analysis
among the stratified African American participants, after
correction for asthma type, there was association between
ABP1 47 C/T, HRH4 413 C/T, and HNMT-1639 C/T genotypes
and pharmacodynamic response (Figures 2, 3). ABP1 47 CC
genotype was associated with higher Emax (148.2 vs. 117.7
for CT/TT genotype, p = 0.030) (Figure 2A). HNMT-1639
CC genotype was associated with lower Emax (CC 100.85 vs.
137.06 CT/TT, p = 0.008) (Figure 2B). HRH4 413 CC genotype
was associated with lower Emax (121.44 vs. 190.08 for CT/TT
genotype, p = 0.005) as well as lower AUEC (CC 5525.04 vs.
9522.64 for CT/TT, p= 0.009) (Figures 3A,B respectively).
TABLE 1 | Demographic characteristics of participants.
Characteristics Mean ± SD or % (N)
Age (years) 12.1 ± 3.1
Male 58 (94)
White (non-Hispanic) 54 (88)
Black (non-Hispanic) 35 (57)
Hispanic 11 (18)
Weight (kg) 52.1 ± 22.3
Height (cm) 150.6 ± 15.8
BMI 22.2 ± 6.8
Allergic Asthma 48 (78)
Body Mass Index (BMI).
Demographic characteristics expressed in Mean ± standard deviation (SD) or
percentages (%) and number (N).
DISCUSSION
In this study we revealed an association between histamine
pathway genetic variation and histamine PD response in children
with asthma. These findings begin to elucidate the potential
clinical impact of histamine genetic variation in children and
adults with allergic and inflammatory disease. Furthermore, these
results are important in further understanding how histamine
genetic variation may affect asthma pathophysiology, severity,
and therapeutic response.
Our study results suggest that genetic variation among
genes responsible for histamine degradation (HNMT and ABP1)
results in an increased histamine pharmacodynamic response
profile in children with asthma. Previous investigations of the
impact of histamine degrading enzyme genotype have revealed
functional differences in enzyme kinetics and alterations in
enzyme function. ABP1 4107 SNPs, which are associated with
increased histamine response (increased Emax) in our study,
are reported to result in missense mutations and decreased
enzyme activity (Ayuso et al., 2007; Maintz et al., 2011).
This previous in-vitro work lends biological plausibility to
our findings in children with asthma. Defective histamine
degradation would lead to accumulation of histamine in the
body, saturation of the receptor site, and stabilization of the
active form of the receptor, causing a more exaggerated response
at the receptor site. These findings suggest that differences in
genotype among the histamine pathway genes not only result
in in vitro enzymatic changes but also result in measureable
changes in histamine response in humans. We also found
that HNMT-1639 genotype was associated with differences
in Emax. Presence of the HNMT-1639 variant allele was
associated with higher response to histamine. The in vitro
functional consequence of the HNMT-1639 non-coding SNP
is not currently known. As the SNP is present in the 5′-
flanking region adjacent to the HNMT gene, it may affect
translation and expression of the gene resulting in either
increased or decreased expression or function of the enzyme
and histamine degradation. Our current findings suggest that
FIGURE 1 | Comparison of Emax values in wild-type homozygous vs. variant containing genotype children with asthma for ABP1 47, ABP1 4107, and
HNMT-1639.
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FIGURE 2 | Comparison of Emax values in wild-type homozygous vs. variant containing genotype African American children with asthma for ABP1 47
(A) and HNMT-1639 (B).
FIGURE 3 | Comparison of Emax (A) and AUEC (B) in wild-type homozygous vs. variant containing genotype African American children with asthma
for HRH4 413.
the variant may result in decreased expression/function of the
enzyme leading to histamine accumulation and exaggerated
response to histamine which we observed in our study. We
previously found that HNMT-1639 was associated with the
allergic asthma phenotype in African American children (Anvari
et al., 2015). Therefore, this SNP may have significance in disease
pathophysiology and severity particularly among specific racial
groups. ABP1 47 variant genotype was associated with decreased
histamine response in our study, although this SNP has also
been reported to result in a missense mutation and decreased
enzyme activity which would suggest an increase in histamine
accumulation and therefore increased response. However, these
previous in vitro studies found that significantly lower enzyme
activity resulting from the ABP1 47 SNP was only observed
when the particular SNP was inherited in combination with
other ABP1 47 SNPs. These data suggest that ABP1 47 variant
allele containing genotypes may not be causative in reducing
enzyme activity. In addition, these experiments were conducted
within a relatively small number of participants with the ABP1
47 variant genotype (Ayuso et al., 2007). It is plausible that
the ABP1 47 SNP may instead lead to increased activity of
the enzyme. Our results indicate that more work is needed to
determine the functional significance of this particular variant
genotype.
We also conducted a stratified analysis among the two
major racial groups included in the study (African American
and Caucasian) due to our previous findings that histamine
genotype was most strongly associated with allergic asthma
phenotype in African American children (Anvari et al., 2015).
Furthermore, the contributions of histamine to disease are
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particularly important to understand among African American
children due to increased asthma prevalence, morbidity, and
mortality in this group when compared to other racial groups as
well as an increased prevalence of the allergic asthma phenotype
(Akinbami, 2006). HNMT-1639 and ABP1 47 genotype were
both associated with Emax among the African American
children as observed in the combined cohort and results
were identical in that the two SNPs were associated with
increased and decreased response, respectively. HRH4 variant
genotype was also associated with an exaggerated histamine
response in African American children however, the small
sample size for those who possess a variant allele do not
allow conclusions to be drawn regarding genotype/phenotype
relationships. The functional significance of the HRH4 413 C/T
missense mutation is unknown. With the discovery of HRH4
receptor in the 1990s and cloning of the receptor in 2000,
new knowledge was gained about the effects of histamine in
the body (de Esch et al., 2005). It has been revealed that
histamine has far more reaching immunologic effects besides
those typically associated with allergic type response at the H1
receptor. HRH4 activation not only results in production of
allergic cytokines such as IL-4, IL-5, and IL-13 but also causes
leukotriene production and production of pro-inflammaotry
(IL-1 and IL-6) and regulatory cytokines (IL-10) (Jemima
et al., 2014). Therefore, genetic variation of the HRH4 receptor
is likely to have more far reaching effects than stimulating
allergic response and may lead to overall alterations in the
immunologic response among those with asthma and allergic
disease. Attenuation of response with HRH4 inverse agonist
agents, currently in clinical trials, may be even more beneficial
in these patients in the treatment of asthma (Thurmond,
2015).
Previous investigations of histamine genetic variants and
asthma have focused on the association between gene variants
and disease. Conflicting reports exist regarding the association
between SNPs such as HNMT 314CT and ABP 4107and
allergic disease such as asthma, atopic dermatitis, and allergic
rhinitis (Yan et al., 2000; Kennedy et al., 2008; Szczepankiewicz
et al., 2010). We have previously explored histamine pathway
genetic variation among children and adults with asthma.
We did not observe an association between histamine genetic
variation and non-phenotyped asthma. However, histamine
pathway genotype was associated with the allergic asthma
phenotype (Anvari et al., 2015; Raje et al., 2015). As 50–80%
of those with asthma are reported to have allergic asthma,
understanding the contributions of histamine and genetic
variation within the histamine pathway are important. Observed
differences in histamine PD response and the association
with histamine pathway genetic variation among children with
asthma may provide important pieces of information leading
to more precise identification of asthma phenotypes that are
relevant to therapeutic response. Furthermore, the use of
conventional treatments, such as antihistamines, may be re-
visited given newly identified functions of histamine in the
body as patients with more exaggerated histamine response
phenotypes and genotypes may benefit most from these types of
agents.
Our study is limited by the small sample size however our
results are supported by observed associations with histamine
response among SNPs previously found to be associated with an
allergic asthma phenotype (e.g., HNMT-1639 and ABP1 4107)
suggesting that these are indeed relevant SNPs. These results
require further validation in larger cohorts. We also recognize
that the SNPs chosen for investigation may not indeed be
causative in the observed differences in histamine response.
Other variants in linkage with the investigated SNPs may be
more causative or observed response may be due to combination
of inherited SNPs. Our study was considerably limited in the
SNPs included. Further work is needed to explore whole gene
and whole genome variants that may be related to histamine
response. We chose to first investigate the few SNPs that have
been previously investigated and found to potentially have an
association with asthma and/or allergic disease as well as variants
that have a known functional significance in vitro. It is likely that
other variants within these genes may be more important and
that gene variants inherited in combination may work together
in affecting histamine response. Our smaller sample size did
not allow these types of analyses. It should also be considered
that histamine receptors are G-protein coupled receptors and
genetic variation within the downstream pathways of these
receptors may also lead to differences in histamine effects and
response.
In conclusion, this is the first study to translate previously
observed in vitro effects of histamine genetic variation into
apparent differences in pharmacodynamic response in humans.
We identified SNPs among 3 genes responsible for histamine
degradation and response that may be related to histamine
pharmacodynamic effect in children with asthma. Our findings
are important to further understand the contributions of
histamine to asthma pathophysiology, phenotype classification,
and therapeutic response profiles.
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